CAR T-cell Therapy Market to Touch US$24 Billion by 2032, Reports Persistence Market Research

The global CAR T-cell therapy market is experiencing transformative growth, projected to expand from an estimated US$5.8 billion in 2025 to US$24 billion by 2032, reflecting a compound annual growth rate (CAGR) of 25% during the forecast period from 2025 to 2032. This growth trajectory is being driven by a confluence of factors, including rising cancer prevalence, especially hematologic malignancies, and continuous advancements in gene-editing technologies and immunotherapy. As these therapies make significant strides in clinical adoption, both in terms of approval and therapeutic applications, the CAR T-cell therapy market is poised to redefine oncology treatment paradigms worldwide.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/28264

Key Industry Highlights

The CAR T-cell therapy market is seeing notable developments across various disease indications and drug types. Lymphoma, particularly non-Hodgkin lymphoma (NHL), is predicted to account for around 40% of the market share in 2025, as CAR T-cell therapies like Yescarta and Kymriah have demonstrated significant efficacy in treating relapsed or refractory lymphoma. The most rapid growth, however, is anticipated in multiple myeloma, a disease where CAR T-cell therapy is showing immense promise. Abecma, the first FDA-approved CAR T-cell therapy for multiple myeloma, is expected to exhibit the highest CAGR in the coming years.

In terms of regional dynamics, North America will continue to dominate, holding an estimated 45% share of the market in 2025, driven by the U.S. regulatory environment and strong clinical adoption. However, the Asia Pacific region is set to become the fastest-growing market, fueled by increasing cancer prevalence, expanding healthcare infrastructure, and ongoing regulatory modernization efforts.

Market Dynamics

Drivers
A significant driver of CAR T-cell therapy market growth is the increasing prevalence of hematologic cancers such as NHL, acute lymphoblastic leukemia (ALL), and multiple myeloma. The International Agency for Research on Cancer (IARC) reported over half a million cases of NHL globally in 2022, with mortality rates exceeding 50%. This rising patient population, alongside a limited effectiveness of traditional therapies, has created a robust demand for personalized and targeted treatments like CAR T-cell therapies. Innovations in gene-editing technologies, especially CRISPR, and the growing adoption of allogeneic (off-the-shelf) CAR T-cell products further drive growth by improving therapy scalability and reducing costs.

Restraints
Despite its promising prospects, the CAR T-cell therapy market faces significant barriers. The most prominent challenge is the high cost of treatment, which can exceed US$400,000 per patient. Such costs present substantial reimbursement and access barriers, particularly in emerging markets where healthcare systems are less equipped to bear these expenses. Moreover, the complex manufacturing process required for CAR T-cell therapies-such as autologous cell collection, genetic engineering, and reinfusion-poses logistical challenges that can lead to supply chain bottlenecks. COVID-19-related disruptions have highlighted these vulnerabilities, further hampering the timely delivery of treatments.

Opportunities
The burgeoning CAR T-cell therapy market presents several opportunities. The advent of artificial intelligence (AI) and machine learning (ML) technologies in therapy development is poised to optimize treatment personalization, enabling the identification of better patient candidates and improving overall clinical outcomes. Additionally, partnerships between biopharma companies and academic institutions, focusing on advancing CAR T-cell technology and reducing production costs, are expected to drive the market forward. Regulatory agencies' support for accelerated approvals and novel clinical trial frameworks, particularly in emerging markets like Asia Pacific, further strengthens growth opportunities.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/car-t-cell-therapy-market.asp

Category-wise Analysis

Drug Type Insights
As of 2025, Yescarta (Kite Pharma, a Gilead Sciences subsidiary) will dominate the CAR T-cell therapy market with an estimated market share of 35%. Yescarta's leadership is attributed to its early regulatory approvals and its proven clinical efficacy in treating relapsed/refractory large B-cell lymphoma and other hematologic cancers. On the other hand, Abecma, the first CAR T-cell therapy approved for multiple myeloma, is expected to grow the fastest in the market, propelled by increasing disease incidence and expanding treatment indications.

Target Antigen Insights
CAR T-cell therapies targeting CD19-predominantly used for treating B-cell malignancies such as lymphoma and leukemia-are expected to continue their market dominance, holding around 55% of the total market in 2025. These therapies benefit from a large body of clinical data supporting their efficacy in providing durable remissions, particularly for relapsed or refractory cancers. The BCMA-targeted CAR T-cell therapies, designed for treating multiple myeloma, are emerging as the fastest-growing segment. Products like Abecma and Carvykti have demonstrated exceptional clinical results, which, along with regulatory approvals, are driving rapid market expansion.

Disease Indication
Lymphoma remains the largest segment, expected to hold 40% of the market share in 2025, owing to the high global prevalence of the disease and the established clinical efficacy of CAR T-cell therapies. However, multiple myeloma, driven by an aging global population, is emerging as the fastest-growing indication. The market for multiple myeloma therapies is expected to surpass US$42 billion by 2032, further bolstered by ongoing clinical trials and regulatory approvals for new CAR T-cell treatments targeting earlier stages of the disease.

Regional Insights

North America
North America, particularly the U.S., will remain the dominant region in the CAR T-cell therapy market, accounting for approximately 45% of the global market share in 2025. The region's leadership is attributed to a well-established healthcare ecosystem, strong innovation hubs, and regulatory frameworks such as the FDA's support for breakthrough therapies and expedited approvals. Moreover, the presence of major biopharma companies in the U.S. has enabled rapid commercialization of CAR T-cell products.

Europe
Europe is forecast to capture around 30% of the global CAR T-cell therapy market by 2025. Germany, the U.K., France, and Spain will be key contributors, benefiting from regulatory harmonization under the European Medicines Agency (EMA) and a favorable reimbursement landscape for CAR T-cell therapies. The European market is also supported by increased government investment in healthcare infrastructure and ongoing clinical research initiatives to advance CAR T-cell treatments.

Asia Pacific
The Asia Pacific region is poised to become the fastest-growing market for CAR T-cell therapies. Key markets such as China, Japan, India, and ASEAN nations are witnessing increased cancer prevalence, improved healthcare infrastructure, and rising government expenditure on healthcare, which collectively contribute to heightened demand for innovative cancer treatments. In China and Japan, flexible regulatory frameworks are expediting the approval process for novel therapies, presenting substantial opportunities for market players.

Competitive Landscape

The global CAR T-cell therapy market is moderately consolidated, with major players such as Gilead Sciences (Kite Pharma), Novartis, and Bristol-Myers Squibb holding a combined market share of approximately 70%. These industry leaders are leveraging their established product portfolios and strong regulatory relationships to expand their presence across global markets. Smaller biotech firms, while contributing innovative technologies and therapies, face challenges related to scaling up production and achieving widespread commercial adoption.

Key Players:

Key players in the CAR T-cell therapy market include:

Gilead Sciences (Kite Pharma)
Novartis AG
Bristol-Myers Squibb
Legend Biotech Corporation
Cellectis S.A.
Autolus Therapeutics
Adaptimmune Therapeutics
Mustang Bio
Bellicum Pharmaceuticals
MaxCyte
Tessa Therapeutics

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/28264

Recent Developments

Notable industry developments include:

In May 2025, the University of Pennsylvania unveiled an enhanced CAR T-cell therapy, designed to improve T-cell persistence and targeting capabilities, potentially reducing relapse rates.

In October 2025, Kite Pharma's ZUMA-24 study showed that outpatient Yescarta treatment for diffuse large B-cell lymphoma (DLBCL) could significantly reduce hospital stays, offering cost savings and improved patient quality of life.

In March 2025, Cellogen Therapeutics launched the first indigenously developed bi-specific CAR T-cell therapy in India, targeting dual antigens to increase efficacy and reduce resistance while reducing production costs by over 90%.

Future Outlook

The CAR T-cell therapy market is on the cusp of significant expansion, driven by advancements in gene-editing technologies, increased funding for research and development, and supportive regulatory frameworks across key regions. The ongoing efforts to address the high cost of treatment, improve manufacturing scalability, and expand the range of treatable diseases are expected to further catalyze market growth. As the patient pool for CAR T-cell therapies continues to grow, particularly in emerging economies, the market is set to evolve into a cornerstone of oncology treatment, offering hope to millions of cancer patients globally.

Read More Related Reports:

Impedance Based Teer Measurement Systems Market https://www.persistencemarketresearch.com/market-research/impedance-based-teer-measurement-systems-market.asp
Neonatal Phototherapy Devices Market https://www.persistencemarketresearch.com/market-research/neonatal-phototherapy-devices-market.asp
Lung Cancer Liquid Biopsy Market https://www.persistencemarketresearch.com/market-research/lung-cancer-liquid-biopsy-market.asp
Fecal Calprotectin Test Market https://www.persistencemarketresearch.com/market-research/fecal-calprotectin-test-market.asp
Veterinary Catheters Market https://www.persistencemarketresearch.com/market-research/veterinary-catheters-market.asp
Guillain Barre Syndrome Diagnostics Market https://www.persistencemarketresearch.com/market-research/guillain-barre-syndrome-diagnostics-market.asp
Dermatology Imaging Market https://www.persistencemarketresearch.com/market-research/dermatology-imaging-market.asp
Endocrine Testing Market https://www.persistencemarketresearch.com/market-research/endocrine-testing-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.